D. Serin

1.6k total citations
73 papers, 1.2k citations indexed

About

D. Serin is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D. Serin has authored 73 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 28 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D. Serin's work include Cancer Treatment and Pharmacology (29 papers), Breast Cancer Treatment Studies (27 papers) and Advanced Breast Cancer Therapies (9 papers). D. Serin is often cited by papers focused on Cancer Treatment and Pharmacology (29 papers), Breast Cancer Treatment Studies (27 papers) and Advanced Breast Cancer Therapies (9 papers). D. Serin collaborates with scholars based in France, Belgium and United Kingdom. D. Serin's co-authors include P. Fumoleau, M. Namer, R. Largillier, B. Audhuy, Jean‐François Morère, Thierry Lesimple, Véronique Dièras, Hubert Orfeuvre, E. Vuillemin and Jacques Bonneterre and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

D. Serin

67 papers receiving 1.2k citations

Peers

Countries citing papers authored by D. Serin

Since Specialization

Citations

This map shows the geographic impact of D. Serin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Serin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Serin more than expected).

Fields of papers citing papers by D. Serin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Serin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Serin. The network helps show where D. Serin may publish in the future.

Co-authorship network of co-authors of D. Serin

This figure shows the co-authorship network connecting the top 25 collaborators of D. Serin. A scholar is included among the top collaborators of D. Serin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Serin. D. Serin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000) 2013 ·European Journal of Cancer ·Catherine Delbaldo, D. Serin, M Mousseau, (unknown), B. Audhuy, Franck Priou, Jean François Berdah, É. Teissier, (unknown), Laurent Zelek, Emmanuel Quinaux, Marc Buyse, Pascal Piedbois	7
2	Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer 2012 ·Annals of Oncology ·Xavier Pivot, Gilles Romieu, Hervé Bonnefoi, Jean‐Yves Pierga, Pierre Kerbrat, J P Guastalla, Alain Lortholary, Marc Espié, P. Fumoleau, D. Serin, J.P. Jacquin, Christelle Jouannaud, María Rios, Sophie Abadie‐Lacourtoisie, N. Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, D. Khayat, Iris Pauporté, A. Kramar	13
3	High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer 2011 ·British Journal of Cancer ·Étienne Brain, Christelle Lévy, D. Serin, Henri Roché, M. Spielmann, R. Delva, Corinne Veyret, L. Mauriac, María Rios, Anne‐Laure Martin, M. Carolina Jimenez, Bernard Asselain, M. Gauthier, Franck Bonnetain, P. Fumoleau	6
4	Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases 2009 ·Critical Reviews in Oncology/Hematology ·B. Cutuli, (unknown), D. Serin, Youlia Kirova, (unknown), C. Lemanski, B. De Lafontan, (unknown), P. Maingon, H. Mignotte, C. Tunon de Lara, Julien Edeline, Frédérique Penault‐Llorca, P. Romestaing, Catherine Delva, (unknown), Yazid Belkacémi	125
5	Male breast cancer (MBC). Analysis of treatment strategies in 489 cases 2008 ·European Journal of Cancer Supplements ·B. Cutuli, (unknown), D. Serin, (unknown), (unknown), C. Lemanski, B. De Lafontan, (unknown), (unknown), Yazid Belkacémi	1
6	Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients 2007 ·Oncology ·Jean‐Emmanuel Kurtz, Frédérique Rousseau, Nicolás Meyer, T. Delozier, D. Serin, (unknown), (unknown), P. Dufour	11
7	Decision-making and breast cancer clinical trialsHow experience challenges attitudes 2007 ·Contemporary Clinical Trials ·Julien Mancini, Jean Genève, Florence Dalenc, Dominique Genre, Alain Monnier, Pierre Kerbrat, R. Largillier, D. Serin, María Rios, Helen M. Roche	23
8	Le contrôle de la respiration en radiothérapie 2007 ·ONCOLOGIE ·R. Garcia, (unknown), C. Khamphan, (unknown), N. Pourel, Laurent Mineur, Gaëtan De Rauglaudre, D. Serin, F Reboul	1
9	Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial 2006 ·Annals of Oncology ·Henri Roché, Pierre Kerbrat, Jacques Bonneterre, P. Fargeot, P. Fumoleau, Alain Monnier, P. Clavère, Marie-Josèphe Goudier, P. Chollet, Jean‐Paul Guastalla, D. Serin	48
10	Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study 2006 ·Annals of Oncology ·Pascal Piedbois, D. Serin, Franck Priou, (unknown), (unknown), (unknown), É. Teissier, Jean François Berdah, Michel Fabbro, B. Valenza, Patrice Herait, Valentine Jehl, Marc Buyse	30
11	Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study 2005 ·British Journal of Cancer ·D. Serin, Mark Verrill, Andrew Jones, T. Delozier, Robert E. Coleman, E.D. Kreuser, K. Mross, (unknown), M. Brandely	10
12	Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) 2003 ·Osteoporosis International ·I. Fogelman, Glen M. Blake, R.W. Blamey, M K Palmer, Willi Sauerbrei, Martin Schumacher, D. Serin, Alan L. Stewart, Wim Wilpshaar	87
13	Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer 2003 ·European Journal of Cancer ·P. Fumoleau, R. Largillier, (unknown), Véronique Dièras, Hubert Orfeuvre, Thierry Lesimple, Stéphane Culine, B. Audhuy, D. Serin, H. Curé, E. Vuillemin, Jean‐François Morère, François Montestruc, (unknown), M. Namer	247
14	Caring about women and cancer (CAWAC) 1999 ·European Journal of Cancer ·Umberto Veronesi, S. von Kleist, (unknown), A. Costa, N. Delvaux, (unknown), A Glaus, (unknown), J. Gordon McVie, (unknown), F. Meunier, S. Pecorelli, D. Serin	41
15	Caring about women and cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancers 1999 ·European Journal of Oncology Nursing ·Umberto Veronesi, S. von Kleist, (unknown), A. Costa, N. Delvaux, (unknown), A Glaus, (unknown), J. Gordon McVie, (unknown), F. Meunier, S. Pecorelli, D. Serin	7
16	Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study 1997 ·European Journal of Cancer ·Beat Thürlimann, R. Paridaens, D. Serin, Jacques Bonneterre, Hoffmann-La Roche, Robin Murray, E. Di Salle, Silvana Lanzalone, (unknown), G. Piscitelli	119
17	Prospective randomized study of mitoxantrone (M) and vinorelbine (V) vs fluorouracil (F), epirubicin (E) or adriamycin (A) and cyclophosphamide (C) in patients with advanced breast cancer (ABC) 1997 ·European Journal of Cancer ·F Turpin, D. Serin, G. Ganem, G. Calais, P. Maillart, P. Colin, Grégoire Prévost, (unknown), (unknown), P. Clavère, M. Namer	0
18	Cancer genetics clinics: Target population and consultees' expectations 1996 ·European Journal of Cancer ·Claire Julian‐Reynier, François Eisinger, F Chabal, Y Aurran, Catherine Noguès, Philippe Vennin, Y.-J. Bignon, (unknown), (unknown), D. Serin, (unknown), (unknown), Hagay Sobol	32
19	Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer 1995 ·Clinical Oncology ·C J Williams, V. Barley, G. Blackledge, C.G. Rowland, C. Tyrrell, Florence Bachelot, (unknown), P. Fargeot, M. Namer, (unknown), D. Serin	9
20	Postmenopausal Patients with Node-Positive Resectable Breast Cancer 1993 ·Drugs ·J.P. Gérard, Michel Héry, D Gedouin, Alain Monnier, Marie-Josèphe Goudier, Jean-Philippe Jacquin, (unknown), (unknown), D. Serin, M. Namer, (unknown), P Hurteloup	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact